ZERBAXA (ceftolozane/tazobactam) Patient Assistance Program

Don’t let the high cost of brand specialty resistant Pseudomonas/gram-negative therapy disrupt your treatment. We help eligible patients access Zerbaxa (ceftolozane/tazobactam) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.

HIPAA Compliant

BBB Accredited

Secure Website

Key ​Takeaways:

What Is Zerbaxa Prescription Assistance Program?

Zerbaxa PAP for MDR gram-negative infections.

Eligibility, ID/hospital coordination.

AffordMyPrescriptions eliminates that burden. $69.95/month advocacy.

Pharmacy Price Comparison

Pharmacy(With Coupon)PrIce (30-Day)*You Save W/ Us
Hospital pharmacy

~$650/dose

Save substantially

Inpatient billing

~$700/dose

Save substantially

Specialty Pharmacy

~$500/dose

Save substantially

Specialty Pharmacy

~$420/dose

Save substantially

Costco

~$410/dose

Save substantially

*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.

Our Pricing:

$69.95 Per month

1 Medications

$79.95 Per Month

2 Medications

$89.95 Per Month

3 Medications

$99.95 Per Month

4+ Medications

Why choose us For Your Zerbaxa Prescription Program?

PAP at no cost. Typically inpatient — hospital billing coordination important.

Enroll

Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.

We Advocate

Our specialists help gather documentation, complete applications, and coordinate with program providers.

Receive Medication

Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.

Discount Coupons vs. Patient Assistance Programs

Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Zerbaxa:

Limitations of Coupons

  • Prices fluctuate — savings aren’t guaranteed month-to-month
  • Copay accumulators may prevent savings from counting toward deductible
  • Coupon cards expire and require constant renewal
  • Still $400–$700 per dose per month even with the best discount

  • Can’t be used with Medicare, Medicaid, or government insurance

Advantages of PAP Through Us

  • Fixed $69.95/month — never changes regardless of retail price
  • No expiration — continuous access as long as you qualify
  • Medication supplied directly through the assistance program
  • We manage all paperwork, refills, and annual renewals
  • If denied, we explore alternative savings on your behalf

DO YOU QUALIFY?

Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Zerbaxa assistance.

Not sure if you qualify?  Our pre-qualification check is completely free. If we can’t help, you won’t be charged.

Understanding Zerbaxa:

Zerbaxa combines ceftolozane (a novel cephalosporin with enhanced activity against Pseudomonas aeruginosa) and tazobactam (β-lactamase inhibitor). Particularly useful for drug-resistant Pseudomonas infections — including multidrug-resistant strains with AmpC overexpression or efflux mechanisms.

How Zerbaxa Works:

Pseudomonas aeruginosa has multiple resistance mechanisms — chromosomal AmpC β-lactamase, efflux pumps, porin loss, target modification. Multi-drug-resistant Pseudomonas is a major nosocomial pathogen with limited options.

Ceftolozane is structurally similar to ceftazidime but with enhanced affinity for Pseudomonas PBP3 and resistance to AmpC β-lactamase activity. Tazobactam inhibits ESBL β-lactamases. The combination has improved activity against MDR Pseudomonas vs. traditional anti-pseudomonal β-lactams. Not active against carbapenem-resistant Enterobacterales with KPC carbapenemases (use Avycaz, Recarbrio, or Vabomere for those).

Form and use:

Zerbaxa given as IV infusion over 1 hour every 8 hours. Higher dose (3 g — 2 g ceftolozane / 1 g tazobactam) for HABP/VABP; standard dose (1.5 g — 1 g/0.5 g) for cUTI/cIAI. Renal dose adjustment for CrCl <50.

Generic availability:

No generic. Other agents for MDR Pseudomonas: traditional anti-pseudomonal β-lactams (cefepime, piperacillin/tazobactam, meropenem, imipenem — if susceptible), aminoglycosides (gentamicin, tobramycin, amikacin), fluoroquinolones (ciprofloxacin, levofloxacin — if susceptible), polymyxins (colistin, polymyxin B). For carbapenem-resistant strains: Avycaz, Recarbrio, Vabomere, Fetroja depending on resistance mechanism.

Warnings:

Zerbaxa carries warnings for hypersensitivity reactions (severe, including anaphylaxis — caution in β-lactam allergy), reduced clinical response in patients with renal impairment (creatinine clearance changes during therapy), C. difficile diarrhea, drug-resistant bacteria emergence with inappropriate use.

FAQ (Frequently Asked Questions)

Cost?

$400–$700/dose. Course $8,000–$20,000+. Hospital billing typically includes.

Drug-resistant gram-negative infections — especially MDR Pseudomonas aeruginosa. Inpatient use coordinated by ID specialist with culture/susceptibility data. Not for CRE (use Avycaz/Recarbrio/Vabomere). Not first-line for susceptible infections (use older β-lactams).

Pseudomonas with multiple resistance mechanisms — common in ICU, immunocompromised, prolonged hospitalization, prior antibiotic exposure. Zerbaxa often the agent of choice when standard anti-pseudomonal β-lactams fail. ID consultation essential.

Zerbaxa NOT active against most carbapenem-resistant Enterobacterales (KPC, OXA-48, metallo-β-lactamases). Use Avycaz (KPC, OXA-48), Recarbrio (KPC), Vabomere (KPC), or Fetroja (broad including metallo-β-lactamases) based on resistance pattern.

Caution in severe β-lactam allergy. ID team assesses risk vs. need; allergy testing may be considered.

Important — renal function changes during therapy (especially in critically ill patients). Frequent reassessment and dose adjustment needed.

ID consult to assess alternatives. Hospital charity programs. PAP if uninsured.

Take Control of Your Medication Costs

If facing Zerbaxa cost, we can help coordinate manufacturer PAP and hospital billing. Check eligibility today.

Submit Enrollment Form

Start free by filling out a simple online form.

Receive Welcome Call

Our specialist will contact you for a quick welcome call.

We Manage The Process

Our team handles everything, so you can focus on your health.

Receive Welcome Call

We Manage The Process